April 2021 Update
Now that Covid-19 restrictions are settling down in London, Dermetel is thrilled to announce the launch of multiple clinical trials in the London area and online.
Dermetel is also excited to announce a new relationship with a Germany-based biotechnology business partner overseeing the enzyme replacement therapy refinement, manufacturing, and clinical trial process. We've decided to team up with this external business to speed up our timeline to get to market, facilitating the acquisition of new enzymes and guaranteeing the results the Dermetel community expects. This exciting new partnership means we expect dual phase 1 and phase 2 trials to start from Fall 2021 in both London, UK and Berlin, Germany. We feel confident our new German partner will polish our existing enzymes as well as the new enzymes to meet the many regulatory standards. Of course, we absolutely intend to run American FDA-approved trials after the UK and European trials. It is easier and faster for us to gain approval in the UK and Europe given the wide support for rare disease treatments and the network we've built. We hope Americans avail themselves of our new, free visa attestation service for anyone who may need a Schengen Visa to enter. You will not need to speak German to participate in the German trials; we are conducting everything in English. We're really lucky to have found a new way forward after so countless roadblocks due to Covid-19 taking priority over rare disease in many CROs.
It has been extremely difficult given Covid-19 to give precise dates and deadlines when things will be completed, but please rest assured that the ball is moving. We intend to announce more on the list-serve when it's time to sign up for the other trials. Thank you for your patience!